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Abstract To improve posttreatment care for (long-term)
lymphoma survivors in the Netherlands, survivorship clinics
are being developed. As information provision is an impor-
tant aspect of survivorship care, our aim was to evaluate the
current perceived level of and satisfaction with information
received by non-Hodgkin’s lymphoma (NHL), Hodgkin’s
lymphoma (HL) and multiple myeloma (MM) survivors,
and to identify associations with sociodemographic and
clinical characteristics. The population-based Eindhoven
Cancer Registry was used to select all patients diagnosed
with NHL, HL and MM from 1999 to 2009. In total, 1,448
survivors received a questionnaire, and 1,135 of them
responded (78.4 %). The EORTC QLQ-INFO25 was used
to evaluate the perceived level of and satisfaction with
information. Two thirds of survivors were satisfied with
the amount of received information, with HL survivors
being most satisfied (74 %). At least 25 % of survivors
wanted more information. Young age, having had chemo-
therapy, having been diagnosed more recently, using inter-
net for information and having no comorbidities were the
most important factors associated with higher perceived
levels of information provision. Although information pro-
vision and satisfaction with information seems relatively
good in lymphoma and MM survivors, one third expressed
unmet needs. Furthermore, variations between subgroups
were observed. Good information provision is known to
be associated with better quality of life. Survivorship care
plans could be a way to achieve this.
Keywords Information provision . Patient satisfaction .
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Introduction
On January 1, 2009 there were approximately 21,000
non-Hodgkin lymphoma (NHL), 5,300 Hodgkin lym-
phoma (HL), and 3,300 multiple myeloma (MM) survi-
vors in the Netherlands [1]. These numbers are expected
to increase to approximately 32,000 NHL, 6,300 HL
and 4,300 MM survivors by 2020 [1]. This substantial
rise will result in an increasing health care burden in
haematology, especially indolent lymphomas and MM,
which both are characterised by a prolonged clinical
course with repeated relapses and slow but ongoing
progression [2].
S. Oerlemans (*) :O. Husson : F. Mols : L. V. van de Poll-Franse
Research Department, Comprehensive Cancer Centre South,
PO Box 231, 5600 AE Eindhoven, the Netherlands
e-mail: s.oerlemans@ikz.nl
S. Oerlemans :O. Husson : F. Mols : L. V. van de Poll-Franse
Center of Research on Psychology in Somatic Diseases (CoRPS),
Tilburg University,
Tilburg, the Netherlands
P. Poortmans
Department of Radiation therapy, Institute Verbeeten,
Tilburg, the Netherlands
H. Roerdink
Department of Oncology and Hematology, Twee Steden Hospital,
Tilburg, the Netherlands
L. A. Daniels : C. L. Creutzberg
Department of Clinical Oncology, Leiden University Medical
Center,
Leiden, the Netherlands
Ann Hematol (2012) 91:1587–1595
DOI 10.1007/s00277-012-1495-1
To improve care for this growing group of cancer survivors,
a nationwide initiative of haematologists, radiation oncologists,
epidemiologists and internists has founded a Working Group
named “BETTER” (“BETER” in Dutch), which is currently
developing protocols for standardized long-term care for HL
and NHL survivors and establishing survivorship clinics. The
goals of these clinics are to minimize the occurrence and
influence of late effects and to improve survivors’ quality of
life (QoL) by: informing survivors about long-term risks, ad-
vice preventive measures, suggest screening and improve af-
tercare by providing rehabilitation programmes [3].
Patient information is an essential component of cancer
care and rehabilitation [4]. Patients, who are well informed
about their cancer, treatment, and aftercare, are more likely
to complete their therapy and are less anxious thereafter [5,
6]. Providing adequate information to cancer patients can
reduce the psychological burden and improve patients’ QoL
and their satisfaction with care [7, 8]. This is important since
lymphoma and MM survivors report lower QoL compared
to normative populations even years after diagnosis [9, 10].
Up to now, no studies have investigated the perceived
level of and satisfaction with information provision in NHL,
HL and MM survivors. If factors associated with informa-
tion satisfaction are known, health care providers can better
give adequate information to those who need it, which can
contribute to an improved quality of care and QoL. The aim
of the present study was therefore to measure the perceived
level of, and satisfaction with information received by sur-
vivors of indolent NHL (I-NHL), aggressive NHL (A-
NHL), HL and MM, and to identify associations with socio-
demographic and clinical characteristics for each tumour
type.
Methods
Setting and population
This study is part of a dynamic longitudinal population-
based survey among lymphoma and MM survivors regis-
tered within the Eindhoven Cancer Registry (ECR) of the
Comprehensive Cancer Centre South and is embedded in
Population-Based HAematological Registry for Observa-
tional Studies. The ECR records data on all patients who
are newly diagnosed with cancer in the southern part of the
Netherlands, an area with 2.3 million inhabitants, 18 hospi-
tal locations and 2 large radiotherapy institutes. The ECR
was used to select all patients who were diagnosed with
NHL, HL and MM between January 1, 1999 and January 1,
2009. We included all subtypes of indolent (including
chronic lymphocytic leukaemia-like) and aggressive B cell
NHL, HL and MM as defined by the International Classifi-
cation of Diseases for Oncology-3 codes [11].
Deceased patients were excluded by linking the ECR
database with the Central Bureau for Genealogy. Ethical
approval for the study was obtained from a regional, certi-
fied Medical Ethics Committee.
Data collection
Data collection took place in 2009 and was done within
PROFILES (Patient Reported Outcomes Following Initial
treatment and Long-term Evaluation of Survivorship). PRO-
FILES is a registry for the study of the physical and psy-
chosocial impact of cancer and its treatment from a
dynamic, growing population-based cohort of both short-
and long-term cancer survivors. PROFILES contains a large
web-based component and is linked directly to clinical data
from ECR. Details of the data collection method have been
previously described [12]. Data from the PROFILES regis-
try will become available for noncommercial scientific re-
search, subject to study question, privacy and confidentiality
restrictions, and registration (www.profilesregistry.nl).
In May 2009, patients between 1 and 10 years after
diagnosis were included in the study and received the
first questionnaire. In November 2009, patients diag-
nosed between May and November 2009 were invited
to participate.
Study measures
The Dutch version of the European Organisation for
Research and Treatment of Cancer (EORTC) QLQ-
INFO25 questionnaire was used to evaluate the per-
ceived level of and satisfaction with information among
NHL, HL and MM patients [13]. This 25-item question-
naire incorporates four information provision subscales:
perceived receipt of information about the disease, med-
ical tests, treatment and other care services. Additional-
ly, it contains several single items on receiving written
information or information on CD or tape/video and
items on the satisfaction with and helpfulness of the
received information. Answer categories range from
one (not at all) to four (very much), except for four
items which have a two-point scale. Furthermore, an
open question is asked on what topics survivors would
like to receive more information on. After linear trans-
formation, all scales and items range in scores from 0 to
100, with higher scores indicating better perceived in-
formation provision. The questionnaire has been inter-
nationally validated, and internal consistency for all
scales is good ( >0.70), as is test–retest reliability (in-
terclass correlations >0.70) [14]. Our data revealed
Cronbach’s alphas of 0.75 (disease), 0.88 (medical test),
0.88 (treatment) and 0.82 (other services) for the four sub-
scales, respectively. In addition to the EORTC QLQ-INFO25,
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we asked patients two single questions about the use of
internet for seeking additional information, which could be
answered with either yes or no.
Comorbidity at time of survey was categorized
according to the adapted Self-administered Comorbidity
Questionnaire [15]. Questions on survivors’ marital sta-
tus and educational level were also added to the ques-
tionnaire. Clinical information was available from the
ECR that routinely collects data on tumour character-
istics, including date of diagnosis, histology, Ann Arbor
stage (where appropriate) [16], primary treatment and
patients’ background characteristics, including gender
and date of birth.
Statistical analysis
All statistical analyses were performed using SPSS version
17.0 (Statistical Package for Social Sciences, Chicago, IL,
USA) and p values of <.05 were considered statistically
significant. For the EORTC QLQ-INFO25, we used a score
of ≥10 points difference on subscales to define a clinical
important difference [17].
Differences in sociodemographic and clinical character-
istics between respondents, non-respondents and patients
with unverifiable addresses and between tumour types were
compared with a chi-square, t test or its nonparametric
equivalent where appropriate.
Multi-item scales of the EORTC QLQ-INFO25 were
included in the analyses if at least half of the items from
the scale were answered, according to the EORTC QoL
guidelines [13, 14, 18]. ANOVA and chi-square were per-
formed to investigate mean differences between tumour type
(independent variables) and the EORTC QLQ-INFO25
scales (dependent variables).
Multivariate regression analyses were performed to
investigate the independent association of sociodemo-
graphic and clinical characteristics with the subscales
of the EORTC QLQ-INFO25. All sociodemographic
and clinical variables were included; this was deter-
mined a priori. Stage was only included in the analyses
for A-NHL and HL since it was not available for I-
NHL and MM (Table 1).
Logistic regression analyses were performed with re-
ceived information satisfaction as outcome measure, one
for the total group and four for the tumour types.
Therefore, patients were categorized into two groups:
(a) patients who were unsatisfied or only a little satis-
fied, classified as unsatisfied and (b) patients who were
quite satisfied or very satisfied, classified as satisfied.
Again, all sociodemographic and clinical variables were
included. Stage was only included in the analyses for
A-NHL and HL since stage was not available in I-NHL
and MM.
Results
Patient and tumour characteristics
Of the 1,448 lymphoma and MM survivors who were sent a
questionnaire, 1,135 (78 %) completed it. Non-respondents
were more recently diagnosed and less often diagnosed with
stage I disease. Furthermore, they were less often treated
with chemotherapy compared to respondents. Patients with
unverifiable addresses were younger, diagnosed less recent,
less often treated with chemotherapy and more often had
active surveillance as primary treatment compared to
respondents. There were no differences in response accord-
ing to tumour type or gender (Table 1).
Participating HL survivors were significantly younger,
more often had a job and reported fewer comorbid condi-
tions than I-NHL, A-NHL and MM survivors. MM survi-
vors were most recently diagnosed compared to the other
three tumour groups (Table 2).
Satisfaction with and amount of information
Satisfied cancer survivors (n0724; 67 %) perceived to have
received more information (disease, medical tests, treatment
and other services) and found the information more useful
than dissatisfied patients (n0411; 33 %), with mean differ-
ences ranging between 46 and 74 points (all p<0.01).
In total, 29 % of survivors would have liked to receive
more information (29 % I-NHL, 25 % A-NHL, 30 % HL
and 29 %MM). Most frequently mentioned topics to receive
more information about were cause and course of disease
(45 % I-NHL, 59 % A-NHL, 24 % HL and 54 % MM), late
effects of treatment (46 % I-NHL, 37 % A-NHL, 50 % HL
and 30 % MM) and psychosocial aftercare (10 % I-NHL,
23 % A-NHL, 26 % HL and 30 % MM).
Associations with perceived level of and satisfaction
with information
Mean scores on perceived level of and satisfaction with infor-
mation on all scales were the highest for HL survivors and the
lowest for I-NHL survivors (Table 3). Furthermore, HL sur-
vivors found the information more useful compared to all
other tumour groups.
Multivariate linear regression analyses including all
patients in one model showed that receiving more disease-
related information was associated with having no comorbid
conditions, using internet for information and hospital (β0 .11;
p<.01; Table 4). More information on medical tests was
associated with less comorbidity, high education and use of
internet. Furthermore, receiving more information about treat-
ment and other services was associated with younger age,
having had chemotherapy, less comorbidity and hospital (β
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between .08 and .10; p<.05). Being diagnosed with I-NHL
and being under active surveillance were associated with a
lower perceived level of receiving information about treat-
ment. Satisfaction with information was independently asso-
ciated with having had chemotherapy and negatively
associated with comorbidity.
Additional multivariate analyses within the different tu-
mour types showed similar findings (data not shown in table).
Younger age (β between −.13 and −.46; p<.05) and a more
recent diagnosis (β between −.10 and −.20; p<.05) were
frequently positively associated with perceived information
provision, whereas comorbidity (β between −.13 and −.23;
p<.05) was frequently negatively associated with perceived
information provision.
I-NHL survivors with a low or medium educational
level reported lower levels of treatment information (β0−.15;
p<.05) compared to those who were highly educated. A-NHL
survivors with stage II or III disease (β0 .22; p<.01) or those
who received chemotherapy (β0 .17; p<.01) reported higher
perceived levels of information compared to those who did
not. HL survivors with a low educational level (β0 .23; p<.05)
and those using internet (β0−.18; p<.05) reported higher
levels of perceived information. Lastly, MM survivors under
active surveillance reported lower perceived levels of infor-
mation about treatment (β0−.45; p<.05) compared to patients
who were actively treated.
Discussion
In the present study among 1,135 NHL, HL and MM sur-
vivors, two thirds of survivors were satisfied with the
Table 1 Sociodemographic and clinical characteristics of questionnaire respondents, non-respondents and patients with unverifiable addresses
Respondents Non-respondents Patients with unverifiable addresses p value
N01,135 N0313 N0271
Tumour type 0.06
I-NHL 443 (39 %) 140 (45 %) 110 (41 %)
A-NHL 375 (33 %) 80 (26 %) 82 (30 %)
HL 164 (14 %) 37 (12 %) 44 (16 %)
MM 153 (14 %) 56 (23 %) 35 (13 %)
Age (at time of survey) (mean±SD) 61.6 (14) 60.5 (16) 57.2 (16) <0.01
<55 312 (28 %) 104 (33 %) 113 (42 %)
55–69 452 (40 %) 99 (32 %) 79 (29 %)
≥70 369 (33 %) 110 (35 %) 79 (29 %)
Years since diagnosis (mean±SD) 3.7 (2.7) 3.2 (3.0) 3.9 (2.9) <0.01
0–1 313 (28 %) 130 (42 %) 71 (26 %)
2–4 422 (37 %) 92 (29 %) 102 (38 %)
5–7 264 (23 %) 46 (15 %) 56 (21 %)
8–10 136 (12 %) 45 (14 %) 42 (16 %)
Gender 0.38
Male 677 (60 %) 184 (59 %) 147 (55 %)
Female 457 (40 %) 127 (41 %) 120 (45 %)
Stage at diagnosis <0.01
I 248 (22 %) 52 (17 %) 65 (24 %)
II 220 (19 %) 57 (18 %) 39 (14 %)
III 183 (16 %) 40 (13 %) 42 (16 %)
IV 218 (19 %) 50 (16 %) 58 (21 %)
Unknown 266 (23 %) 114 (36 %) 67 (25 %)
Primary treatment
Radiotherapy 88 (7.8 %) 17 (5.4 %) 20 (7.4 %) 0.09
Chemotherapy 515 (45 %) 118 (38 %) 106 (39 %) 0.02
Chemotherapy+radiotherapy 239 (21 %) 56 (18 %) 52 (19 %) 0.11
Active surveillancea 233 (21 %) 89 (23 %) 71 (26 %) <0.01
Stem cell transplantation 58 (5.1 %) 16 (5.1 %) 8 (3.0 %) 0.07
I-NHL indolent non-Hodgkin lymphoma, A-NHL aggressive non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma
a Patients are under active surveillance and receive no therapy
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Table 2 Sociodemographic and clinical characteristics of cancer survivors, stratified by tumour type
I-NHL A-NHL HL MM p value
N0443 N0375 N0164 N0153
Age (at time of survey) (mean±SD) 64.1 (11) 63.3 (14) 46.6 (15) 66.1 (10) <0.01
<55 90 (20 %) 90 (24 %) 112 (69 %) 20 (13 %)
55–69 199 (45 %) 136 (36 %) 38 (23 %) 79 (52 %)
≥70 154 (35 %) 148 (40 %) 13 (8.0 %) 54 (35 %)
Years since diagnosis (mean±SD) 4.0 (2.7) 3.5 (2.6) 4.4 (2.9) 2.4 (2.3) <0.01
0–1 100 (23 %) 108 (29 %) 36 (22 %) 69 (45 %)
2–4 169 (38 %) 144 (38 %) 50 (31 %) 59 (39 %)
5–7 113 (26 %) 85 (23 %) 49 (30 %) 17 (11 %)
8–10 61 (14 %) 38 (10 %) 29 (18 %) 8 (5.2 %)
Gender 0.10
Male 266 (60 %) 239 (64 %) 89 (54 %) 83 (55 %)
Female 177 (40 %) 136 (36 %) 75 (46 %) 69 (45 %)
Stage at diagnosis <0.01
I NA 118 (32 %) 30 (18 %) NA
II NA 90 (24 %) 83 (51 %) NA
III NA 68 (18 %) 33 (20 %) NA
IV NA 93 (25 %) 17 (10 %) NA
Unknown NA 6 (1.6 %) 1 (0.6 %) NA
Primary treatment
Radiotherapy (only) 64 (14 %) 12 (3.2 %) 4 (2.4 %) 8 (5.2 %) <0.01
Chemotherapy (only) 157 (35 %) 235 (63 %) 65 (40 %) 58 (38 %) <0.01
Chemotherapy+radiotherapy 14 (3.2 %) 98 (26 %) 94 (57 %) 33 (22 %) <0.01
Active surveillancea 187 (42 %) 25 (6.7 %) 1 (0.6 %) 20 (13 %) <0.01
Stem cell transplantation 8 (1.8 %) 22 (5.9 %) 0 (0 %) 28 (18 %) <0.01
Comorbidity <0.01
None 108 (26 %) 103 (30 %) 75 (48 %) 26 (19 %)
1 122 (30 %) 118 (34 %) 46 (30 %) 43 (31 %)
2 90 (22 %) 65 (19 %) 14 (9.0 %) 35 (26 %)
3 or more 90 (22 %) 60 (17 %) 20 (13 %) 33 (24 %)
Marital status 0.41
Partner 353 (81 %) 287 (79 %) 122 (75 %) 116 (77 %)
No partner 84 (19 %) 77 (21 %) 41 (25 %) 35 (23 %)
Education level 0.11
Low 69 (16 %) 62 (17 %) 16 (9.8 %) 30 (20 %)
Medium 264 (61 %) 219 (61 %) 99 (61 %) 95 (63 %)
High 101 (23 %) 80 (22 %) 48 (29 %) 27 (18 %)
Current occupation <0.01
Employed 166 (46 %) 128 (45 %) 112 (84 %) 39 (34 %)
Not working/retired 198 (54 %) 155 (55 %) 21 (16 %) 76 (66 %)
Follow-up care <0.01
No 42 (10 %) 32 (10 %) 12 (8 %) 30 (24 %)
2–4 times a year 324 (80 %) 245 (74 %) 81 (52 %) 95 (75 %)
Once a year 35 (9 %) 52 (16 %) 62 (40 %) 1 (1 %)
Once every 2 years 3 (1 %) 2 (1 %) 1 (1 %) 0 (0 %)
I-NHL indolent non-Hodgkin lymphoma, A-NHL aggressive non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma, NA not
available; education levels included low no/primary school, medium lower general secondary education/vocational training, or high pre-university
education/high vocational training/university.
a Patients are under active surveillance and receive no therapy
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amount of received information about their haematological
malignancy, respectively 65 % of I-NHL, 67 % of A-NHL,
74 % of HL and 68 % of MM survivors. However, varia-
tions were observed, and at least a quarter of survivors
wanted more information, with large differences between
hospitals (range, 24–40 %).
Younger age, having had chemotherapy, using internet
for information and having no comorbid conditions
appeared to be the most important factors associated with
higher perceived levels of information provision. Analyses
per tumour type showed similar findings. Worth mentioning
is that in the analyses per tumour, I-NHL, A-NHL and MM
survivors who had been diagnosed more recently had higher
perceived levels of information provision, which possibly
indicates that information provision has improved with time.
However, it is also possible that recall bias influenced these
findings, for those diagnosed more recently, the information
received is still fresh in their memory and by the more
frequent contacts with their physician in the phase more
closely to diagnosis.
Our findings that the perceived level of information provi-
sion is associated with age, education, time since diagnosis
and disease stage are in line with other studies [19–24].
Studies have shown that older and lower educated patients
tend to ask fewer questions during their visit with their phy-
sician, and might therefore receive less information [25, 26].
Furthermore, older patients have been found to take a more
passive role in interaction with their physician and have a
greater reliance that their physician will provide all informa-
tion [24]. In addition, higher educated patients are more likely
to seek information from other sources such as the internet and
consequently obtain more information [24].
The results of our study, with 67 % of survivors being
satisfied with the amount of information received, were
different compared to a study among mostly early-stage
melanoma survivors in which only 39 % of survivors indi-
cated to be satisfied [22]. These differences might be
explained by the more chronic level and intense treatment
of lymphoma and MM compared to early-stage melanoma.
In addition, lymphoma and MM survivors will have more
visits with the physician and therefore a possible improved
information provision. Patients’ satisfaction is also influ-
enced by patients’ expectations of the course of their disease
[27]. Patients’ expectations can vary widely, depending of
the type of tumour [27]. HL survivors may be more satisfied
with and score better on perceived information since they
have a better prognosis compared to NHL and MM
survivors.
Survivors who were satisfied with the received informa-
tion scored significantly and clinically relevant higher on all
information provision subscales and on the usefulness of
information scale compared to the unsatisfied survivors. To
improve information provision in the group of unsatisfied
survivors, physicians could screen their patients by asking if
they are satisfied with the amount of information received,
and when unsatisfied, physicians can ask what the patients’
information needs are.
To provide the needed (written) information to patients,
physicians should think of the educational level of the
information provision. Patients with a lower educational
level and patients with a low level of literacy will need extra
help to understand the information. In the USA, more atten-
tion is being paid to health literacy [20, 21, 28], i.e. “the
degree to which individuals have the capacity to obtain,
process and understand basic health information and serv-
ices needed to make appropriate health decisions” [29], than
in the Netherlands. Since our and other studies have ob-
served that lower educated survivors report worse scores,
more attention should be paid to providing information on a
basic comprehensive level [19, 22, 23].
Table 3 Mean EORTC QLQ-INFO25 subscale scores (±SD) according to tumour type
I-NHL A-NHL HL MM p value
N0443 N0375 N0164 N0153
EORTC QLQ-INFO25 Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Information about disease 50 (22) 53 (20) 56 (16) 51 (22) <0.05a
Information about medical tests 63 (22) 64 (23) 68 (21) 65 (23) 0.15
Information about treatment 41 (24) 50 (21) 57 (19) 47 (24) <0.01b
Information about other services 16 (21) 25 (24) 27 (22) 22 (21) <0.01c
Satisfaction with information 60 (28) 61 (26) 66 (25) 61 (28) 0.15
Usefulness of information 62 (25) 66 (24) 73 (21) 62 (25) <0.01d
% Yes % Yes % Yes % Yes
Want more information 29 % 25 % 30 % 29 % 0.48
Want less information 3 % 3 % 2 % 1 % 0.74
EORTC-QLQ INFO25 scales 0–100: a higher score reflects better perceived information received
I-NHL indolent non-Hodgkin lymphoma, A-NHL aggressive non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma
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One third of survivors would have liked to receive more
information. The topic that was mentioned most often was
information on late effects (37–50 %) followed by informa-
tion on the cause and course of the disease (24–59 %) and
psychosocial aftercare (10–26 %). Inviting survivors for the
“BETTER” initiative could be an efficient solution to ad-
dress these lasting information needs and leads to improved
health care perception.
The present study has a few limitations. Although infor-
mation was present concerning demographic and clinical
Table 4 Standardized betas of multivariate linear regression analyses evaluating the association of independent variables with the information
provision subscales
Disease Medical tests Treatment Other Satisfaction with received information
(Beta) (Beta) (Beta) (Beta) (odds±95 % CI)
Tumour type
I-NHL −0.07 −0.07 −0.12** −0.09 0.89 (0.52–1.52)
A-NHL −0.05 −0.07 −0.04 0.03 0.783 (0.48–1.28)
HL Ref Ref Ref Ref Ref
MM −0.05 0.02 −0.03 0.00 0.81 (0.43–1.56)
Age −0.05 0.01 −0.12** −0.11** 1.00 (0.99–1.01)
Years since diagnosis −0.01 0.01 0.02 −0.05 0.97 (0.92–1.03)
Gender
Male Ref Ref Ref Ref Ref
Female 0.01 0.02 −0.01 −0.01 0.77 (0.58–1.03)
Chemotherapy
No Ref Ref Ref Ref Ref
Yes 0.03 −0.01 0.14* 0.14** 1.81 (1.04–3.13)*
Radiotherapy
No Ref Ref Ref Ref Ref
Yes −0.08 −0.06 −0.06 −0.07 1.00 (0.68–1.45)
Active surveillance
No Ref Ref Ref Ref Ref
Yes −0.09 −0.08 −0.16** −0.06 1.39 (0.76–2.55)
Stem cell transplantation
No Ref Ref Ref Ref Ref
Yes 0.07 0.06 0.05 0.06 1.51 (0.73–3.13)
Comorbidity
None Ref Ref Ref Ref Ref
1 −0.07 −0.04 −0.07 −0.02 0.74 (0.51–1.52)
2 −0.07 −0.05 −0.14** −0.03 0.55 (0.36–0.85)**
3 or more −0.90* −0.90* −0.07* −0.01 0.55 (0.36–0.84)**
Marital status
Partner Ref Ref Ref Ref Ref
No partner 0.01 0.02 −0.02 0.00 1.21 (0.84–1.73)
Education level
Low 0.02 −0.04 −0.02 −0.03 0.85 (0.52–1.38)
Medium −0.03 −0.08* −0.06 −0.05 0.81 (0.57–1.16)
High Ref Ref Ref Ref Ref
Use of internet
Yes Ref Ref Ref Ref Ref
No −0.08* −0.07* −0.04 −0.03 0.97 (0.71–1.32)
I-NHL indolent non-Hodgkin lymphoma, A-NHL aggressive non-Hodgkin lymphoma, HL Hodgkin lymphoma, MM multiple myeloma; Education
levels included low no/primary school, medium lower general secondary education/vocational training, or high pre-university education/high
vocational training/university
*p<.05; **p<.01
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characteristics of the non-respondents and patients with
unverifiable addresses, it remains unknown why non-
respondents declined to participate in the study. In addition,
the cross-sectional design of our study limits the determina-
tion of causal associations between the study variables.
Furthermore, the mean time since diagnosis was 3.7 years,
which could influence the recall effect of information re-
ceived. However, in the case of indolent lymphoma and
MM patients who visit their physicians more often, this
may not have been a major problem as the majority of those
patients (95 %) was still under active follow-up.
The strengths of our study are the population-based sam-
pling frame instead of a hospital-based sampling frame, the
high response rate and the large range in elapsed time since
diagnosis. This facilitates to extrapolate the results to a
broad range of lymphoma and MM survivors.
In conclusion, although information provision and satis-
faction with information is relatively good in lymphoma and
MM survivors, one third of the survivors were not satisfied
with the perceived information provision, and variations
between subgroups of patients were observed. The differ-
ences found between the participating hospitals with an
assumed similar patient population suggest that there
remains room for improvement. As survival of NHL, HL
and MM has improved over the past decades and the numb-
ers of long-term survivors increase, late effects of therapy
become more important. Optimal, tailor-made and repeated
information provision will lead to improved patient satisfac-
tion and QoL. Implementation of survivorship care plans
could contribute to the improvement of information provi-
sion [30].
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